Moderna (MRNA) June weekly IV elevated as shares sell off 6.4%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'
June 9, 2022 11:09 AM EDTArgus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We are maintaining our BUY rating on Focus List selection Moderna Inc. (NYSE: MRNA). The company develops therapeutics and... More
